OncoMatch/Clinical Trials/NCT06926920
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Is NCT06926920 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Sacituzumab Govitecan-hziy (SG) for triple negative breast cancer.
Treatment: Sacituzumab Govitecan-hziy (SG) — The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this study are to assess the safety and tolerability of SG given at alternate dose and schedule, to assess the effect on objective response rate (ORR) and progression-free survival (PFS).
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) negative (CPS < 10 by IHC 22C3 assay) (CPS < 10)
Tumors must be PD-L1 negative, defined as tumor PD-L1 combined positive score (CPS) < 10 using the PD-L1 immunohistochemistry (IHC) 22C3 assay
Required: UGT1A1 wild-type
During Phase 1 safety run-in, individuals must be UGT1A1 wild-type
Allowed: PD-L1 (CD274) CPS ≥ 10
individuals with tumor CPS ≥ 10 will be eligible if they received an anti-PD-(L)1 agent in the adjuvant or neoadjuvant setting or if they cannot be treated with an anti-PD-(L)1 agent due to a comorbidity
Allowed: UGT1A1 any genotype
After Phase 1 safety run-in, individuals with any UGT1A1 genotype may be eligible
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy — locally advanced or metastatic
refractory to or relapsed after at least one prior standard-of-care chemotherapy regimen or systemic therapy given for locally advanced or metastatic disease
Cannot have received: topoisomerase 1 inhibitor
Prior treatment with a topoisomerase 1 inhibitor or antibody-drug conjugate (ADC) containing a topoisomerase inhibitor
Cannot have received: antibody-drug conjugate
Prior treatment with a topoisomerase 1 inhibitor or antibody-drug conjugate (ADC) containing a topoisomerase inhibitor
Cannot have received: Trop-2-directed antibody-drug conjugate
Prior treatment with a trophoblast cell-surface antigen 2 (Trop-2)-directed ADC
Lab requirements
Blood counts
Adequate hematologic counts within 2 weeks prior to enrollment
Kidney function
Adequate renal function
Liver function
Adequate hepatic function
Adequate hematologic counts within 2 weeks prior to enrollment. Adequate hepatic and renal function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Los Angeles Cancer Network (LACN) - Good Sam · Los Angeles, California
- Winship Cancer Institute - Emory University · Atlanta, Georgia
- The University of Kansas Hospital · Westwood, Kansas
- Siteman Cancer Center · St Louis, Missouri
- West Cancer Centre · Germantown, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify